TABLE 5.
Main studies evaluating emotional impact and COVID-19 in oncology patients using validated scales to measure psychopathological symptomatology compared with our results.
| Author | Country/region | N |
Cancer patients’ characteristics
|
Scale | Results | ||
| Type of patient | Treatment/follow-up | Type of tumor | |||||
| Gultekin et al., 2021 | EU | 1251 | Ambulatory patients | Scheduled for surgery (without oncologic treatment yet). Under active treatment (46%). Under follow-up. |
Gynecological cancers in any stage | Online survey HADS; HADS-T not reported. ≥11; “significant case” of psychological morbidity (abnormal) 8–10; “borderline case” 0–7; “normality” (healthy individuals) |
HADS-A (≥ 11): 35.3% HADS-A (8–10): 24.1% HADS-D (≥ 11): 30.6% HADS-D (8–10): 20.6% |
| Letaief-Ksontini et al., 2020 | Turkey | 91 | NR | NR | NR | HADS | HADS-A: 29.7% HADS-D: 69.2% |
| Wang et al., 2020 | China | 6213 | Ambulatory patients | NR | All types of tumors | Online survey Anxiety; GAD-7 Depression: PHQ-9 |
Anxiety rate: 17.7% Depression rate: 23.4% |
| Agua et al., 2020 | Spain | 2293 | Ambulatory patients | Active treatment (50%). Follow up. |
All types of tumors | Online survey Kessler Psychological Distress Scale K-6 |
Psychological distress rate: 34.2% |
| Lou et al., 2020 | United States | 543 | Ambulatory patients | Oncology (55.4%)* and non-oncology patients (44.6%). *Active treatment (25.6% of the oncologic patients included) |
All types of tumors | Online survey Anxiety; GAD-7 Depression: PHQ-8 |
1 Anxiety rate: 26% 1 Depression rate: 26.7% |
| van de Poll-Franse et al., 2020 | Denmark | 4094 | Ambulatory patients | Oncology (4094)* and non-oncology patients (977). *Active treatment (27%) |
All types of tumors | HADS | HADS-A: 11.8% (v. 11.2% in non-oncology patients) HADS-D: 9.9% (v. 12.2%) |
| Mogami et al., 2021 | Japan | 34 | Ambulatory patients | Active treatment (65%). Follow up. |
Gynecological cancers in any stage |
HADS: HADS-A; ≥ 8 HADS-D; ≥ 8 |
Anxiety rate: 33% Depression rate: 43% |
| Toquero Diez et al., 2020 (Psico-Covid) | Spain | 104 | Ambulatory patients | Active treatment (100%). | All types of tumors | Staff-supervised HADS: HADS-T; ≥10 HADS-A; ≥7 HADS-D; ≥4 |
HADS-T: 52.8% HADS-A: 42.3% HADS-D: 58.6% |
EU, European Union; USA, United States of America; NR, Not reported; HADS, hospital anxiety and depression scale; HADS-T, hospital anxiety and depression scale—total/emotional distress; HADS-A, hospital anxiety and depression scale—anxiety subscale; HADS-D, hospital anxiety and depression scale—depression subscale; O-HDH, onco-hematologic day hospital; GAD-7, 7-item generalized anxiety disorder; PHQ-8/PHQ-9, 8-9 item patient health questionnaire; GHQ-12, 12-item general health questionnaire. 1Results only for oncology patients in active treatment.